Related Experiment Video
Updated: Jul 4, 2026
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Muscle myostatin signalling is enhanced in experimental cancer cachexia
P Costelli1, M Muscaritoli, A Bonetto
1Department of Experimental Medicine and Oncology Università di Torino, Italy. paola.costelli@unito.it
European Journal of Clinical Investigation
|June 27, 2008
Summary
Cancer cachexia involves altered myostatin signaling, with early reductions in follistatin and increased SMAD activity. Targeting the myostatin pathway offers a potential therapeutic strategy for muscle wasting in cancer.
Area of Science:
- Muscle physiology and molecular biology
- Cancer research
- Biochemistry
Background:
- Myostatin, a transforming growth factor-beta superfamily member, negatively regulates skeletal muscle mass.
- Myostatin deletion causes muscle overgrowth, while overexpression or administration leads to atrophy.
- Cancer cachexia is characterized by significant muscle depletion.
Purpose of the Study:
- Investigate myostatin signaling modulation in cancer cachexia using a rat hepatoma model.
- Determine the role of tumor necrosis factor-alpha in cancer cachexia-induced muscle loss.
Main Methods:
- Western blotting to assess myostatin, follistatin, and activin receptor type IIB protein levels.
- Immunoprecipitation for circulating myostatin and follistatin.
- Electrophoretic mobility shift assay for SMAD transcription factor DNA-binding activity.
- Administration of pentoxifylline, a tumor necrosis factor-alpha inhibitor.
Main Results:
- Early (day 4) in tumor hosts: reduced follistatin, enhanced SMAD DNA-binding activity; myostatin levels unchanged.
- Later (day 7) in tumor hosts: increased myostatin and follistatin; SMAD activity unchanged.
- Pentoxifylline treatment reduced myostatin expression and SMAD activity (day 4), and increased follistatin (day 7), partially correcting muscle depletion.
Conclusions:
- Myostatin signaling is modulated during cancer cachexia.
- Tumor necrosis factor-alpha influences myostatin pathway components.
- The myostatin pathway represents a potential therapeutic target for cancer cachexia.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:13Formation of Muscle Fibers from Myoblasts
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...